[go: up one dir, main page]

MX2016006329A - Composiciones solidas de trigliceridos y usos de estas. - Google Patents

Composiciones solidas de trigliceridos y usos de estas.

Info

Publication number
MX2016006329A
MX2016006329A MX2016006329A MX2016006329A MX2016006329A MX 2016006329 A MX2016006329 A MX 2016006329A MX 2016006329 A MX2016006329 A MX 2016006329A MX 2016006329 A MX2016006329 A MX 2016006329A MX 2016006329 A MX2016006329 A MX 2016006329A
Authority
MX
Mexico
Prior art keywords
solid compositions
triglicerids
triheptanoine
phenylbutyrate
triglycerides
Prior art date
Application number
MX2016006329A
Other languages
English (en)
Other versions
MX383005B (es
Inventor
Emil Kakkis
Steven Jungles
Klopp John
Morris Gabrielle
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of MX2016006329A publication Critical patent/MX2016006329A/es
Publication of MX383005B publication Critical patent/MX383005B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

La presente invención incluye composiciones sólidas de triglicéridos con uno o más ácidos grasos, como triheptanoina y fenilbutirato de glicerol, y sus usos terapéuticos; las composiciones sólidas se pueden preparar mediante secado por pulverización u otros procesos.
MX2016006329A 2013-11-14 2014-11-14 Composiciones solidas de trigliceridos y usos de estas. MX383005B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14
PCT/US2014/065693 WO2015073816A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Publications (2)

Publication Number Publication Date
MX2016006329A true MX2016006329A (es) 2016-09-06
MX383005B MX383005B (es) 2025-03-13

Family

ID=53058066

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006329A MX383005B (es) 2013-11-14 2014-11-14 Composiciones solidas de trigliceridos y usos de estas.
MX2021001790A MX2021001790A (es) 2013-11-14 2016-05-13 Composiciones solidas de trigliceridos y usos de estas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001790A MX2021001790A (es) 2013-11-14 2016-05-13 Composiciones solidas de trigliceridos y usos de estas.

Country Status (18)

Country Link
US (6) US20160243071A1 (es)
EP (2) EP3782610A1 (es)
JP (4) JP2017501972A (es)
KR (1) KR102291310B1 (es)
CN (2) CN113181158A (es)
AR (2) AR099353A1 (es)
AU (1) AU2014348470B2 (es)
CA (2) CA3197154A1 (es)
CL (1) CL2016001130A1 (es)
ES (1) ES2833294T3 (es)
IL (1) IL245588B (es)
MX (2) MX383005B (es)
MY (1) MY177028A (es)
PE (1) PE20161024A1 (es)
PH (1) PH12016500821A1 (es)
RU (1) RU2016123169A (es)
TW (1) TWI640327B (es)
WO (1) WO2015073816A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113181158A (zh) * 2013-11-14 2021-07-30 奥特吉尼克斯制药公司 三酸甘油酯的固体组合物及其用途
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
WO2020041871A1 (en) 2018-08-27 2020-03-05 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
CA2212047C (en) 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
CN100408031C (zh) * 1999-02-05 2008-08-06 贝勒研究院 含七碳脂肪酸甘油三酯的营养补充剂或药物制剂
EP1628622A4 (en) * 2003-05-20 2008-12-17 Baylor Res Inst FIVE AND FIFTH CARBON FATTY ACIDS FOR THE TREATMENT OF METABOLISM DISORDERS AND AS FOOD SUPPLEMENTS
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
CA2784420C (en) 2004-07-02 2020-11-10 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
CA2599667C (en) * 2005-03-10 2014-12-16 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxy carboxylic acids
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
US8642012B2 (en) 2008-04-29 2014-02-04 Hyperion Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
CA2801206A1 (en) * 2010-06-14 2011-12-22 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
CN101919453B (zh) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
PT2760479T (pt) 2011-09-30 2017-07-21 Horizon Therapeutics Llc Métodos de monitorização da terapêutica com fármacos eliminadores de azoto
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
WO2013158616A1 (en) * 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency
HK1216717A1 (zh) 2012-12-13 2016-12-02 Baylor Research Institute At Dallas 用於治療葡萄糖轉運體1缺乏症的三庚酸甘油酯
CN113181158A (zh) * 2013-11-14 2021-07-30 奥特吉尼克斯制药公司 三酸甘油酯的固体组合物及其用途

Also Published As

Publication number Publication date
CL2016001130A1 (es) 2017-01-20
TWI640327B (zh) 2018-11-11
EP3068383A4 (en) 2017-11-08
IL245588B (en) 2021-08-31
US20250120936A1 (en) 2025-04-17
US20250120934A1 (en) 2025-04-17
MY177028A (en) 2020-09-02
CN105764497A (zh) 2016-07-13
CA2929688C (en) 2023-06-13
CN113181158A (zh) 2021-07-30
TW201609189A (zh) 2016-03-16
AR099353A1 (es) 2016-07-20
AU2014348470B2 (en) 2020-01-30
KR102291310B1 (ko) 2021-08-23
AR130666A2 (es) 2025-01-08
JP2020111585A (ja) 2020-07-27
CA2929688A1 (en) 2015-05-21
WO2015073816A1 (en) 2015-05-21
ES2833294T3 (es) 2021-06-14
CA3197154A1 (en) 2015-05-21
RU2016123169A (ru) 2017-12-19
MX2021001790A (es) 2021-04-19
EP3068383A1 (en) 2016-09-21
US20160243071A1 (en) 2016-08-25
KR20160084407A (ko) 2016-07-13
IL245588A0 (en) 2016-06-30
US20250120935A1 (en) 2025-04-17
PE20161024A1 (es) 2016-11-10
MX383005B (es) 2025-03-13
JP2024129109A (ja) 2024-09-26
EP3068383B1 (en) 2020-09-16
PH12016500821A1 (en) 2016-06-13
JP2022107017A (ja) 2022-07-20
EP3782610A1 (en) 2021-02-24
AU2014348470A1 (en) 2016-05-26
US20200069631A1 (en) 2020-03-05
JP2017501972A (ja) 2017-01-19
US20230181513A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
CL2019000609A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
CL2018002794A1 (es) Compuestos bicíclicos
CL2019000610A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
CL2016002300A1 (es) Combinaciones de principios activos insecticidas y nematocidas
MX379262B (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
UY34773A (es) Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos
MX2017002469A (es) Composiciones de matrices extracelulares.
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
MX2016006329A (es) Composiciones solidas de trigliceridos y usos de estas.
IL252674A0 (en) Production of transgenic canola with little or no saturated fatty acids
LT3219316T (lt) Riebalų rūgščių mišinys (r.r.g., riebalų rūgščių grupė), skirtas naudoti uždegiminių patologijų gydymui
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
IL241245A (en) Bicyclo [2.2.1] acid gpr120 modulators
MX2014015039A (es) Inhibidores de fbx03.
EP3625339A4 (en) CHANGES TO LYSINE DECARBOXYLASE ENZYMES
DK3082795T3 (da) Sammensætninger af omega 3 fedtsyrer til behandling af sygdomme, der involverer skader på nervesystemet
FI20150044A7 (fi) Rasvahappokoostumus
EP3849499A4 (en) COMPOSITIONS CONTAINING LINOLEIC ACID
CL2019000042A1 (es) Composiciones farmacéuticas
EP3362085C0 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES INVOLVING MUCIN
CL2019003502A1 (es) Compuestos de piridina y pirazina.
LT3482761T (lt) Kompozicijos, apimančios kromoglicino rūgštį, skirtos dermatito gydymui